

**CANM  
ACMN**

**CANADIAN ASSOCIATION OF NUCLEAR MEDICINE  
*ASSOCIATION CANADIENNE DE MÉDECINE NUCLÉAIRE***

**2016 ANNUAL SCIENTIFIC MEETING  
RÉUNION SCIENTIFIQUE ANNUELLE 2016**

**FACULTY / CONFÉRENCIERS**

*Several Speakers' presentations will be available on the  
CANM Website after the conference.*

*Plusieurs présentations seront disponibles sur le  
site Web de l'ACMN après la conférence.*

**FACULTY LIST / LISTE DES CONFÉRENCIERS****Abrams, Doug N.**

Dr. Abrams is currently working at Eastern Health as part of the team setting up the Newfoundland and Labrador Centre for Molecular Imaging and Research. Prior roles were Assistant Director of the Winnipeg Health Sciences Radiopharmacy and Director of the Edmonton Radiopharmaceutical Centre. He has a strong interest in radiopharmaceutical development and translation of PET and SPECT radiopharmaceuticals into diagnostic and therapeutic use. He is an active promoter of radiopharmacy and radiopharmaceutical research and is actively involved in several national and international professional organizations. He has been president of the Canadian Association of Radiopharmaceutical Scientists, Prairie Provinces Chapter, Society of Nuclear Medicine, Canadian Society of Nuclear Medicine and founding president of the Canadian College of Radiopharmaceutical Scientists. He is a member of the Nuclear Medicine Alliance and has served on the SNMMI radiopharmaceutical Sciences organizing committee. He was a member of the Health Canada Regulatory Working Group on Medical Isotopes and helped co-coordinate and co-chair several Health Canada Regulatory Workshops. Most recently, he became a founding member of the CANM-CARS regulatory consultative group recently formed to liaise with Health Canada on regulatory matters of interest to the Nuclear medicine community.

**Anderson, Peter**

**Education:** BSc: University of New Brunswick; MD and Urology Residency: Dalhousie University  
MEd: Acadia University

**Current positions:** Professor and Director of Education, Urology Department, Dalhousie University Faculty of Medicine, Active Staff, IWK Health Centre

**Past Achievements:** Royal College Physicians and Surgeons Canada: Member of Council 2006-2015, Chair, Professional Development Committee 2009-2014, Canadian Urological Association: President 2013-14

**Barnes, David**

Dr. Barnes is a graduate of Memorial University of Newfoundland. He practiced family medicine at the University of Waterloo before joining Dalhousie for a residency in radiology and nuclear medicine. He completed a nuclear medicine residency at the University of Western Ontario prior to joining the faculty at Dalhousie in 1989. He has held a number of administrative positions locally, regionally and nationally prior to being appointed Clinical Chief at the Central Zone NSHA and Head, Department of Diagnostic Radiology, Dalhousie University in 2008. His research interests have included Bone SPECT, Spondylarthropathies, MIBG and Thromboembolic disease with more current interest in Quality issues in medical imaging. Dr. Barnes is currently the chair of the specialty committee for Nuclear Medicine for the Royal College of Physicians and Surgeons of Canada.

**Berry, Robert,**

Robert Berry is Section Head of Research and Interventional Radiology at the QE II HSC in Halifax, NS. After completing medical school at UBC, he specialized in diagnostic radiology at Dalhousie University before doing further subspecialty training in vascular and interventional radiology at The University of Colorado.

His research interests include Interventional oncology, endovascular treatment of PVD and thrombosis disasters.

**Bethune, Drew**

Short Biography – Former head of Thoracic Surgery Dalhousie and QE2 Health Sciences Center, Medical Director Nova Scotia Provincial Cancer Programme, Medical Director QE2 Cancer Programme. MD Dalhousie University, FRCS(C) General Surgery McGill, MSc Experimental Surgery McGill (Lymphoscintigraphy Thoracic Lymph Nodes), Thoracic Surgery University of Chicago.

Interests Thoracic Oncology, Cancer Care Delivery Systems, Innovation in Cancer.

**Bourguet, Patrick**

Patrick Bourguet, né en 1950, est professeur de Biophysique et Médecine Nucléaire à l'Université de Rennes, France. Diplômé ingénieur de l'École Supérieure d'Electricité à Paris en 1973, il obtient son PhD en physique du solide en 1979 à Rennes. Ayant débuté ses études de médecine à l'âge de 25 ans, il obtient son MD en 1983 et devient spécialiste de médecine nucléaire en 1985. Nommé Maître de Conférences de l'Université de Rennes en 1985, puis Professeur en 1990, il sera successivement chef du service de médecine nucléaire, directeur du Département d'imagerie médicale de 1990 à 2000, puis directeur du Centre Régional de lutte contre le cancer de 2000 à 2010. Patrick Bourguet a exercé de nombreuses responsabilités nationales ou internationales: Président de la Société Française de MN de 1998 à 2002 et membre du CA depuis lors, trésorier puis Président de l'EANM de 2005 à 2011, Président du Comité Consultatif des Universités, section MN depuis 2003, Président du Cancéropôle Grand Ouest depuis 2010. Il a dirigé pendant de nombreuses années un groupe de recherche sur le "développement de nouveaux radiopharmaceutiques en oncologie". Il est l'auteur ou le co-auteurs de près de 200 articles et de plus de 40 conférences. Il est actuellement chairman de l'«imaging group» à l'EORTC, Bruxelles.

**Bower, Jonathan**

Mr. Jonathan Bower is a Nuclear Medicine Technologist at the QEII Health Sciences Center in Halifax, Nova Scotia. Mr. Bower graduated from Dalhousie University in 2010 with a Bachelors Degree in Nuclear Medicine Technology. Having completed a specialty practice in PET/CT he has continued to advance his interest through clinical practice and involvement at the national level with the Canadian Association of Medical Radiation Technologists (CAMRT). Mr. Bower is also highly involved in the regulation of MRTs in Nova Scotia and currently sits as the Vice President of the Nova Scotia Association of Medical Radiation Technologists (NSAMRT).

**Burrell, Steven**

Dr. Steven Burrell originally obtained a master's degree in Engineering. Following Medical School he completed a combined Diagnostic Radiology and Nuclear Medicine residency at Dalhousie, and is RCPC certified in both specialties. This was followed by a fellowship in the Harvard Joint Program in Nuclear Medicine, with emphasis on oncology and cardiac imaging.

Dr. Burrell is a staff radiologist at the QEII Health Sciences Centre and is Clinical Head of Nuclear Medicine at the IWK Health Centre. His clinical interests include oncology imaging and radioisotope therapy, cardiac imaging, brain imaging, and bone mineral density.

Dr. Burrell is past Research Director for Dalhousie Diagnostic Radiology, and past Residency Program Director for Dalhousie Nuclear Medicine.

**Castonguay, Mathieu**

Originally from New Brunswick, Mathieu Castonguay obtained his MD from Dalhousie University in 2006, followed by residency in Anatomical Pathology at the University of Western Ontario and fellowship at the Mayo Clinic in Rochester, MN. Since 2012, he has been practicing cardiothoracic pathology at the QE2 Health Sciences Centre and Dalhousie University in Halifax, Nova Scotia.

**Clarke, James**

Dr. Clarke is a dual certified Radiologist and Nuclear Medicine physician working in the Nuclear Medicine and Cardiac Imaging Divisions at the QEII Health Sciences Centre. He is currently serving as the program

director for the Dalhousie University Nuclear Medicine residency training program in Halifax, Nova Scotia. Following his residency, Dr. Clarke completed a fellowship in Cardiac MRI at the Stephenson CMR centre in Calgary, Alberta. In his clinical practice he interprets Cardiac MRI, CT, PET, nuclear medicine and cardiac catheterization studies and for 8 years he performed diagnostic cardiac catheterization procedures in Halifax.

### **Couillard, François**

François Couillard is the CEO of the CAMRT. His career encompasses 30 years of developing and executing strategies in healthcare organizations, including Johnson & Johnson and Nordion. He has also managed the operations of two of Canada's largest non-profits, The Canadian Red Cross and VON Canada (a home care provider). He is a Certified Management Consultant (CMC), and holds a MBA in Marketing and International Business from McGill University. He also holds a Bachelor of Engineering (Chemical Engineering) from the Université de Sherbrooke.

François enjoys working with communities of interest on high stakes issues. He is the instigator of Canada's Multi-Stakeholder Working Group on Medical Isotopes and has served on numerous advisory councils and boards, including Canada's Advisory Council on National Security and Europe's Association of Imaging Producers and Equipment Suppliers (AIPES) and CORAR, the Council on Radionuclides and Radiopharmaceuticals. He currently serves as the President of the board of the Ottawa Community Immigrant Service Organization and on the Management Committee of HEAL, Canada's Health Action Lobby group. If you are looking for him outside working hours he can usually be found riding his bike or cross-country skiing in the hills outside Ottawa.

### **Darvesh, Sultan**

Darvesh, Sultan, MD, PhD, FRCPC Professor of Medicine (Neurology/Geriatric Medicine) and Medical Neuroscience DMRF Irene MacDonald Sobey Chair in Curative Approaches to Alzheimer's Disease The Maritime Brain Tissue Bank (Director) Assistant Dean, Research-Clinical Departments Dalhousie University.

### **Di Carli, Marcelo**

Dr. di Carli is a Professor of Radiology and Associate Professor of Medicine at Harvard Medical School, the Chief of the Division of Nuclear Medicine and Molecular Imaging and Director of Noninvasive Cardiovascular Imaging Program at the Brigham and Women's Hospital. His areas of research focus include cardiovascular physiology and pathophysiology, with an emphasis in coronary heart disease; physiology and pathophysiology of coronary circulatory function in diabetes and pre-diabetic states, including obesity and the metabolic syndrome, and outcomes research. His primary area of expertise is cardiovascular nuclear medicine and molecular imaging, and the specialized field of Positron Emission Tomography (PET), and more recently Cardiac Computed Tomography (CT).

### **Fahey, Frederic H.**

Frederic H. Fahey, DSc, has been the Director of Nuclear Medicine/PET Physics at Boston Children's Hospital since 2003 and is a Professor of Radiology at Harvard Medical School. He received his Doctor of Science from the Harvard School of Public Health in Medical Radiological Physics in 1986. Prior to coming to Boston Children's Hospital, he had worked at Georgetown School of Medicine from 1984 to 1991 and Wake Forest School of Medicine from 1991 to 2003. He served as president of the Society of Nuclear Medicine and Molecular Imaging in 2012-2013. He is a fellow of both the American College of Radiology and the American Association of Physicists in Medicine. His research interests include PET and SPECT instrumentation, image processing, reconstruction of tomographic data and the radiation dosimetry, particularly in the realm of pediatric nuclear medicine. He is actively involved in the Imaging Gently and Image Wisely campaigns as they pertain to nuclear medicine.

**Gambhir, Sanjay**

Dr Sanjay Gambhir is Prof. and Head Nuclear Medicine at Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. He has special interest in newer and evolving technologies specially hybrid imaging in field of Nuclear medicine and its adaptation for growing economy like India. With keen interest in policy making and growth of this specialty in India, Prof. Gambhir has been Past President of Society of Nuclear Medicine, India and Nuclear Cardiological Society of India. Dr Gambhir is advisor to Medical Council of India and National Board of Certification for the specialty of Nuclear Medicine.

**Ginj, Mihaela**

Mihaela Ginj is currently a radiopharmacist at University Health Network in Toronto and an assistant professor in the Department of Medical Imaging at University of Toronto. Mihaela completed her PhD in radiopharmaceutical chemistry at University of Basel in Switzerland in 2005. Her thesis focused on enhancing targeting properties of radiolabelled somatostatin analogs for diagnostic and therapy of neuroendocrine tumors.

When not obsessing over GMP (Good Manufacturing Practice) and radiopharmacy budget, Mihaela's clinical interests focus on improving the access of Canadian patients to diagnostic radiopharmaceuticals approved elsewhere and confirmed to have an impact on treatment decisions. Her research interests also aim at closing the gap between bench and bedside for selected peptide-based therapeutic radiopharmaceuticals targeting various cancers.

She is also a passionate advocate of nuclear medicine, using every formal and informal opportunity to educate the medical community and the general public on the benefits of this discipline.

**Glazebrook, Mark**

Mark Glazebrook is a full time Associate Professor of Orthopaedic Surgery at Dalhousie University with a cross appointment to the School of Biomedical Engineering. He completed his medical training in 1994 and completed specialty training in Orthopaedic Surgery in 1999 at Dalhousie. He then went on to complete a fellowship in Orthopedic Foot & Ankle and Sports Medicine at the University of Western Ontario. This was followed with a PhD in Achilles Tendon Disease at Dalhousie University while working part time in his clinical practice. Dr. Glazebrook devotes 80% of his working time to clinical practice focusing on Orthopedic Foot & Ankle Reconstruction and Sports Medicine. During research time focus is on outcome studies on Evidence Based Medicine, Ankle Arthritis, MTP Arthritis, Bone Graft Substitutes and Achilles tendon rupture care.

**Iles, Sian**

Dr. Iles graduated from medical school at Dalhousie in 1982. Following a joint residency in nuclear medicine and radiology, she did fellowship training at the Mallinckrodt Institute of Radiology in St Louis Missouri. She has worked at the VGH, the IWK and the Cape Breton Regional Hospital and now works at the IWK Health Centre and the Central Zone of Nova Scotia Health. Her clinical sub-specialties are in Breast and Nuclear medicine.

**Jackson, Jeremy**

Jeremy Jackson has been a practicing Nuclear Medicine Technologist at the Moncton City Hospital since 2004. This clinical site has been providing diagnostic SPECT/CT exams for more than 10 years. Since its inception, Jeremy has fully embraced the technology and has promoted it in a variety of ways. He has been invited to numerous conferences and hospitals to present on SPECT/CT theory, applications, and case studies, to audiences that include a range of medical healthcare professionals. In addition, Jeremy provides preceptorship and hands-on SPECT/CT training, to select students, from both the Saint John (NBCC/UNBSJ/Regional hospital), and Dalhousie School of Health Sciences, Nuclear Medicine Technology programs.

Jeremy received his BSc from the University of New Brunswick (Fredericton) in 1995. He then graduated from the Joint New Brunswick Community College / Saint John Regional Hospital diploma program in

Nuclear Medicine Technology in 2003 and subsequently acquired both the Canadian (CAMRT) and American (NMTCB) certifications. In addition, he has completed the didactic and clinical requirements for the CAMRT specialty certificate in CT and holds the CTIC designation.

### **Lambert, Raymond**

Raymond Lambert MD,FRCP(C), ABNM Formation:

Nuclear Medicine Residence:

- o Universite de Sherbrooke
- o University of Western Ontario
- Pediatric Nuclear Clinical Fellowship:
  - o Hospital for Sick Children , University of Toronto

Practice:

- Director of Nuclear Medicine and PET unit at CHU-Sainte-Justine, Universite de Montreal
- Chef of Nuclear Medicine unit at Montreal Children Hospital, McGill University
- Associate member of Centre Hospitalier Universite de Montreal (CHUM)
- Associate member of Hopital Hotel-Dieu de Saint-Jerome

University affiliation :

- Associate professor Universite de Montreal

### **Levin, Daniel**

Dr. Levin is a Nuclear Medicine physician at Health Sciences Centre and head of the Section of Nuclear Medicine at the Grace Hospital in Winnipeg. He works in combined adult and pediatric departments, with a focus on pediatric Nuclear Medicine and pediatric and adult PET/CT.

Dr. Levin obtained a BSc in Physics and completed his MD at The University of Manitoba. He trained in Nuclear Medicine at McGill University and l'Université de Montréal in Montréal. He pursued additional pediatric Nuclear Medicine training at The Hospital for Sick Children, Toronto. Dr. Levin is an associate professor at The University of Manitoba. He has been a Board member of the Pediatric Imaging Council of the SNMMI, and was Chair of the Specialty Committee in Nuclear Medicine at The Royal College of Physicians and Surgeons of Canada. He currently is a member of the board of the Canadian Association of Nuclear Medicine.

### **Mang'era, Kennedy**

Dr. Kennedy Mang'era is Chief Operating Officer at the Canadian Isotope Innovations Inc. (CIIC) in Saskatoon. CIIC is focused on development of linear accelerator produced Mo99/Tc99m, low specific activity Mo99/Tc99m generator technologies and medical isotope provision for clinical use. He was until October 2015 the Director of the Radiopharmacy at the Winnipeg Regional Health Authority and is Assistant Professor of Radiology and of Pharmacy at the Faculty of Health Sciences, University of Manitoba.

Dr. Mang'era is a B. Pharmacy graduate of the University of Nairobi, a Masters and Ph.D. graduate in Radiopharmaceutical Sciences from the Katholieke Universiteit Leuven in Belgium and did post-doctoral research at the University of Massachusetts with morpholino oligonucleotides and the pre-targeting approach to tumor diagnosis and therapy.

Dr. Mang'era is active professionally and is among others, current President of the Canadian Association of Radiopharmaceutical Sciences, Co-Chair of the CARS-CANM Regulatory Working Group, and member of the National Multi-Stakeholder Working Group on Isotopes. He was Secretary of the Canadian Association of Nuclear Medicine (CSNM) and co-chaired the CSNM Annual Meeting in Winnipeg in 2009.

### **Manos, Daria**

Daria Manos obtained a BA from McGill University in 1996 and then completed her medical degree and radiology residency at Dalhousie University where she also served as chief resident. She finished her fellowship in Thoracic Radiology at Vancouver General Hospital in 2007. She is currently associate

professor of medicine at Dalhousie University, head of Thoracic Radiology at the QEII Health Sciences Centre and chair of the Lung Cancer Screening Working Group at Cancer Care Nova Scotia. She is currently involved in lung cancer initiatives with Cancer Care Nova Scotia, The Canadian Association of Radiologists and the Canadian Partnership Against Cancer. Dr Manos has received teaching awards from the RSNA and from Dalhousie University.

### **McEwan, Sandy**

Dr. McEwan is an internationally recognized expert in the fields of radioisotope therapy, molecular imaging and imaging biomarkers. Through a series of competitive awards he established the Edmonton PET Centre in 2002, and has built the program into major support infrastructure for the Department of Oncology, and collaborators across the University. He is the current lead in the Edmonton Led Consortium established by Natural Resources Canada to demonstrate the feasibility of manufacturing technetium-99m using a mid energy medical cyclotron. Through Federal and Provincial granting initiatives he has been awarded over \$14 million to support this research.

His clinical practice and clinical research interests are in thyroid cancer and neuroendocrine tumours. He has established the largest radioisotope therapy program in Canada, and with Dr Murray has developed the novel hypothesis that low-dose hypersensitivity explains the mechanism of action of this form of treatment. He introduced <sup>177</sup>Lu Octreotate to the Cross Cancer Institute in 2010. The Edmonton PET program has established a library of 8 research radio tracers that are routinely available to translational and clinical researchers on campus. Collaborations with the Edmonton Radiopharmacy Centre have enabled us to become a regional supplier of PET radiopharmaceuticals.

He has been past president of the Society of Nuclear Medicine in the United States and also of the Canadian Association of Nuclear Medicine. Dr. McEwan is also a member of the Society of Nuclear Medicine Clinical trial Network. In these roles he represented the discipline at numerous venues, including discussions with the U.S. and Canadian federal governments, the FDA, industry and other medical specialty societies. In addition, he proposed that Molecular Imaging and Imaging Biomarkers should be a major focus of the future use of medical isotopes and radiotracer technologies in the management of patients with cancer and other diseases. He was Special Adviser on medical isotopes to the Federal Minister of Health from 2009 to 2011, and he sits on the Nuclear Energy Agency's High-Level Group on medical isotopes. Dr. McEwan has taken on the role of Commissioner for the Canadian Nuclear and Safety Commission and he is currently Chair of the Department of Oncology at the University of Alberta.

### **Mohan, Ravi**

Ravi Mohan, MD DPhil Msc FRCPC (Diagnostic Radiology), FRCPC (Nuclear Medicine)

- Undergrad (in Human Biology) and Masters (in Respiratory Physiology) at University of Toronto (1997).
- Doctorate and Post Doctoral Fellowship in "Autonomic Control of the Heart" at the University of Oxford (2002)
- Completed MD @ University of Toronto in 2006
- Completed Radiology FRCPC @ University of Ottawa in 2011
- Completed Nuclear Medicine FRCPC @ University of Toronto in 2013
  - Since 2013, Staff Radiologist and Nuclear Medicine Physician, Joint Department of Medical Imaging, University Health Network, Toronto Canada

### **Mulroy. Liam A.**

Liam Mulroy obtained his medical degree from Western University in 1986 and completed a family medicine residency at Dalhousie in 1988. After 3 years in general practice he entered radiation oncology residency in Toronto and obtained his Royal College fellowship in 1995.

He returned to Halifax and has been a member of the Department of Radiation Oncology at Dalhousie University for twenty years. He is an Associate Professor within the Faculty of Medicine and is co-chair of the CancerCare Nova Scotia Thoracic Oncology site team. His areas of clinical interest include thoracic,

hematologic and CNS tumours. He has served as a residency program director and Royal College examiner. He is involved in clinical trials led by NCI Canada and other cooperative clinical groups.

**Mut, Fernando,**

Dr. Mut is a nuclear medicine physician graduated from the School of Medicine in Montevideo, Uruguay. He has been involved in education for more than 30 years as a professor of nuclear medicine and is currently Head of Nuclear Medicine in Spanish Association Hospital, Montevideo.

Dr. Mut is Past-President of ALASBIMN. He has been Involved in many activities sponsored by the International Atomic Energy Agency (IAEA) all over Latin-America and has worked as a consultant in headquarters in Vienna, Austria. He is the founder of Iberoamerican Society of Nuclear Cardiology.

**Rajaraman, Murali**

After completing residency at Dalhousie University and a Fellowship at the Princess Margaret Hospital in Toronto, Dr. Murali (Mal) Rajaraman has been a Radiation Oncologist in the Department of Radiation Oncology, Dalhousie University and Nova Scotia Health Authority in Halifax, Nova Scotia for over 20 years. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) and a Diplomate of the American Board of Radiology in Radiation Oncology.

Dr. Rajaraman's clinical expertise are in the areas of Thyroid Cancer, Head & Neck Cancer, Sarcoma, Lung Cancer, and Skin Cancer. Research activities and interests are in the fields of Neosis, Clinical and Research Databases, Thyroid Cancer, PET/CT scan utilization in Oncology and clinical trials. Administrative and academic responsibilities have included membership of the NCIC-CTG Canadian Sarcoma Group Executive Committee, CARO Manpower and Standards Committee, CARO Elekta Research Fellowship Program Selection Committee, Chairmanships of the Cancer Care Nova Scotia Cancer Site Teams in Head and Neck Cancer and Sarcoma (Musculoskeletal Cancer), Thyroid Cancer Canada Medical Advisory Panel, and Associate Member of the Beatrice Hunter Cancer Research Institute (BHCRI).

**Rayson, Daniel**

Dr. Daniel Rayson is a medical oncologist at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Pediatrics at Dalhousie University. He completed his medical training at Dalhousie, with subsequent fellowship training in Internal Medicine and Hematology/Medical Oncology at the Mayo Clinic in Rochester, Minnesota. His main areas of clinical care and research activities are in breast and neuroendocrine oncology. He is past Chair of the Nova Scotia Provincial Breast Cancer Site Team (2000-2009), current Chair of the multidisciplinary Neuroendocrine Tumor Group (2012- ) and past chair of the Clinical Trial Grant Panel Review Committee of the National Cancer Institute of Canada (2006-2009). He has been the Director of the Atlantic Clinical Cancer Research Unit (ACCRU) since 2008, is on the editorial board of the Art of Oncology Section of the Journal of Clinical Oncology and has been section editor of the Cancer Narratives Section of Current Oncology since January, 2013. In January 2015, he became Interim Chief of the Division of Medical Oncology at the QE II Health Sciences Center and Dalhousie University

**Ridgway, Anthony**

Dr. Ridgway was born and educated in the U.K. and completed his B.Sc. and Ph.D. in Biology at McGill University in Montréal. He proceeded to post-doctoral studies and then an Assistant Professorship in the Cancer Research Laboratory and Department of Microbiology and Immunology at the University of Western Ontario. Academic research activities included work on the structure and expression of oncogenes, retroviral regulatory elements, HIV regulatory genes, and inducible expression vectors.

He has been with Health Canada since 1991 and, in 1999, became manager of the Biotherapeutics Division, with responsibility for regulation of a wide range of products, including radiopharmaceuticals. In 2004 he guided the separation of his former division into three new divisions and assumed the new position of Senior Regulatory Scientist in the Office of the Director, in the newly formed Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics, where he holds a range of supervisory and advisory responsibilities, including quality of radiopharmaceutical. He has been active with the ICH\* since



1993, serving on Expert Working Groups addressing the quality of biotechnology products. Since June 2000, he has served on US Pharmacopoeia Committees of Experts, initially for “Cell, Gene and Tissue Therapies” and currently for “General Chapters – Biological Analysis”.

(\*International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use)

### **Schwarz, Sally W.**

Sally Schwarz is a Professor of Radiology at Washington University School of Medicine in St. Louis. She is a Board Certified Nuclear Pharmacist. She has developed and managed the PET Production of PET Radiopharmaceuticals for clinical and clinical research use for over 20 years, established the first PET Nuclear Pharmacy at Washington University in St. Louis, and has been involved in training pharmacy students as part of the PharmD program at St. Louis College of Pharmacy and the University of New Mexico. She served on the USP Expert Committee for 10 years, and was involved in writing the revised USP Chapter <823> which defined the GMP PET production and quality control requirements for PET radiopharmaceuticals for research use. She is the Secretary of the Radioactive Research Committee at Washington University Medical School. She has recognized expertise in preparation of the Chemistry Manufacturing and Control documents, including production and quality control for Investigational New Drugs (INDs and RDRC Applications). She is a member of the American Pharmacist Association (APhA), and the APhA Nuclear Pharmacy SIG. Sally became an APhA fellow in 2009, and will receive the William H. Briner Distinguished Achievement Award at the APhA meeting in March 2016. She served as the Nuclear Pharmacy advocate on the NRC Advisory Committee for the Medical Use of Isotopes (ACMUI) for 6 years. Sally has been a member of the Society of Nuclear Medicine and Molecular Imaging for 30 years, and is currently the President Elect of the SNMMI. Sally will become the SNMMI President in 2016, and is the first pharmacist to hold this position.

### **Seifert, Katherine**

Ms. Seifert is a principal in the consulting firm Seifert and Associates, Inc. located in Ventura, California. She consults in the areas of regulatory compliance and quality for radiopharmaceuticals, nuclear medicine practice, and Positron Emission Tomography, both commercial and investigational. She also is involved in product development and regulatory compliance for Rotem, Inc., a supplier of consumables for PET radiopharmaceutical manufacturing. Ms. Seifert has a background in radiation safety and serves on various Radiation Safety Committees and Radioactive Drug Research Committees for research institutions in the US.

### **Shammas, Amer**

Dr. Amer Shammas is currently the Division Head and Residency Program Director of Nuclear Medicine, Medical Imaging Department at University of Toronto. Dr. Amer Shammas has been Interim Head of the Division of Nuclear Medicine since July 2013 at The Hospital for Sick Children. Dr. Shammas received his medical degree from Damascus University, Faculty of Medicine in Syria. He started his Diagnostic Radiology residency in Syria and completed his Nuclear Medicine residency program at Loyola University Medical Center in Illinois, USA. Subsequently, Dr. Shammas completed a PET fellowship at the University of Pittsburgh Medical Center in Pennsylvania, USA. He then completed his fellowship in Pediatric Nuclear Medicine in the Department of Diagnostic Imaging at The Hospital for Sick Children in 2008. Since then, he has been working as a Nuclear Medicine Physician at The Hospital for Sick Children and project investigator in the Research Institute. He is a member of the Canadian Association of Nuclear Medicine, Radiological Society of North America, and Society of Nuclear Medicine. Dr. Shammas’ main interests are PET imaging and radionuclide therapy.

### **Smith, Nichole**

Nichole Graduated from the QEII/Dalhousie School of Health Sciences Nuclear Medicine Technology Degree Program in 2012. After graduating, Nichole started her career at the QEII Health Sciences Centre. Throughout her three and a half years at the QEII Nichole worked in general nuclear medicine as well as

PET/CT, and the Nova Scotia Provincial Radiopharmacy. Nichole is passionate about the MRT profession and is a volunteer at the provincial and national level. In addition, she has an interest in continuing education, and research. Most recently, Nichole has accepted a new role as an Educator for the Nuclear Medicine program at the QEII/Dalhousie School of Health Sciences.

#### **Snow, Stephanie**

Dr. Snow has been a staff Medical Oncologist at the QEII hospital in Halifax, Nova Scotia and an Assistant Professor at Dalhousie since 2010. After pursuing undergraduate training at McGill, she completed her MD, Internal Medicine and Medical Oncology training at Dalhousie. She treats head and neck, thoracic and GI malignancies. Academically, she has a strong interest in Medical Education, overseeing the Dalhousie Undergraduate Medical Oncology program and contributing to national oncology education initiatives. She participates in clinical research in areas relevant to her treatment sites and also supportive care.

#### **Sperry, Jennifer**

Jennifer Sperry is a nuclear medicine technologist employed by the Nova Scotia Health Authority. She trained at Dalhousie University and starting working at the authority in 2002.

Over the years, she has developed an interest in improving patient and workplace safety. Jennifer has been a preceptor, WHMIS trainer, and super user for the camera and processing systems in the department.

She is married with two grown children and enjoys camping and hiking with her husband.

#### **Urbain, Jean-Luc**

Dr. Urbain has been an active member of the Medical Community for more than 25 years. After earning his Medical Degree, Urbain pursued residency training in Internal Medicine and Medical Imaging. He obtained a Ph.D. in Genetics and Molecular Biology at Temple University, In Philadelphia. Urbain has been Professor of Medicine and Diagnostic Imaging for more than two decades. He has hold leadership positions at Fox Chase Cancer Center, the Cleveland Clinic, the University of Western Ontario and more recently in the Veteran Health Administration. As a teacher and leader Urbain has made significant contribution to the field of Molecular Imaging.

Urbain has extensive experience and expertise in committees and boards leadership and management in integrated health care systems and patient advocacy groups and at regional, national and international levels of government. Urbain has been privileged to work closely with medical associations and government health authorities to mitigate major health crisis, analyzed and helped establish medical resources needs, benchmarks and allocation for key medical service areas. He has served as a consultant and advisor for Pharmaceutical and Medical Systems companies such as Janssen & Janssen, Glaxo, Smith Kline Beecham, GE and Siemens. He has also worked in the medical industry as senior director, advisor and investigator for the clinical validation of new technology/ products.

Urbain current main interests are in Physicians Performance Improvement, Patient Education and Advocacy and Personalized Medicine.”

#### **Vaughan, Peter**

Dr. Peter W. Vaughan is Deputy Minister of Nova Scotia Department of Health and Wellness.

Prior to becoming Deputy Minister, Peter was the president and Chief Executive Officer, and Medical Director of the South Shore District Health Authority. Dr. Vaughan’s international clinical medical experience spans several jurisdictions in Canada, United States, Central America and Europe.

He completed his Master of Public Health at The Johns Hopkins University Bloomberg School of Public Health in Baltimore, Maryland. He has an Honors Bachelor of Arts and a Master of Arts in Philosophy from the University of Guelph, and a Doctor of Medicine from McMaster University in Hamilton, Ontario. He also completed the Queen’s University School of Business Queen’s Executive Program in 2007.

He is also an experienced media spokesperson and public speaker with a long list of writing and production credits including short fiction, humor, travel, international medical news, new media and broadcast television.

### **Vuillez, Jean-Philippe**

Jean-Philippe Vuillez was born in Montélimar, France, in 1960. Doctor of Medicine since 1988, he was successively Resident, Assistant, Master of Conference - Hospital Practitioner Biophysics and University Professor - Hospital Practitioner in the Nuclear Medicine Department of the University Hospital of Grenoble, where he is now head of department as a specialist in Nuclear Medicine and teacher of Biophysics. MD, PhD, he obtained the accreditation to supervise research in 1998.

Very involved in pedagogy, he was Assessor of the Dean for Undergraduate Medical Education and now is Vice Dean for Education, as Director of studies of the Faculty of medicine of Grenoble.

He completed his research as part of the 1039 INSERM Unit led by Professor Catherine Ghezzi, and works on the development of radiopharmaceuticals in oncology (original ligand alphaV-beta3 in particular) for the diagnosis and internal radiotherapy (RIV); it also has a strong involvement in clinical research through several Internal Targeted Radiotherapy studies.

Finally, he is the President of SFMN (French Society of Nuclear Medicine and Molecular Imaging). He has published 75 articles referenced in PubMed including 10 as first author and 12 as last author.

### **Wells, Glenn**

Dr. Glenn Wells received his PhD in Medical Physics from the University of British Columbia. He then worked as a post-doctoral research fellow at the University of Massachusetts Medical Center (Worcester, MA, USA) until he returned to Canada in 2000 to take a position at the Nuclear Medicine department of St. Joseph's Hospital (London, ON). He joined the University of Ottawa Heart Institute at the end of 2006 as a medical imaging physicist and is an Associate Professor in Cardiology at the University of Ottawa. He is an expert in SPECT/CT imaging physics. His research is in image reconstruction and correction methods for attenuation, scatter, camera resolution, and motion with application to both pre-clinical and clinical nuclear medicine. Most recently, his research has focused on dedicated cardiac SPECT cameras and the quantification of myocardial blood flow with dynamic imaging. He has published 59 peer-reviewed papers, 6 book chapters and over 150 conference abstracts.

### **Wiley, Ash**

Ash Wiley was born and raised in New Brunswick, completing a BSCh in Biochemistry at UNB Fredericton before attending medical school Dalhousie University. He then completed a Diagnostic Imaging residency at Dalhousie University, and then a residency in Nuclear Medicine at UBC in Vancouver, BC. He has been working in the Dept of Diagnostic Imaging at the QEII Health Sciences Centre in Halifax, NS since July 2016.

### **Wilson, John**

John is the Cyclotron Facility Manager at both the Edmonton PET Centre (EPC) and the new Medical Isotope and Cyclotron Facility (MICF) in Edmonton, Alberta. He received his degree in organic chemistry (nucleosides) in the Department of Chemistry and later was introduced to radiochemistry in the Department of Pharmacy at the University of Alberta. He joined the EPC in 2001 during construction to operate and manage the cyclotron and to help develop the radiochemistry for FDG and other PET radiopharmaceuticals of interest at the Cross Cancer Institute in Edmonton.

The cyclotron facility has since become a major radiopharmaceutical production and distribution site and gained an international reputation for innovative target design.

Since coming into the field of PET, research interests have been split between the development of [<sup>18</sup>F] fluorine and [<sup>11</sup>C] carbon chemistry and the cyclotron targetry involved in the production of various radionuclides. Recently, John was involved in the development of a high current solid target and processing system to demonstrate the feasibility of producing <sup>99m</sup>Tc directly on the cyclotron. The MICF in Edmonton was funded through NRCan to advance this technology to commercialization.

**Zabel, Pamela**

Pamela Zabel, MScPhm, BScPhm: ,Coordinator of the London Regional Nuclear Pharmacy, has over 30 years of experience in Radiopharmacy , EANM Specialty Certification in Radiopharmacy as well as Certification in Business Administration and Certification in Clinical Trials. As an Assistant Professor in Medical Imaging, Western University, Pamela has taught many current Canadian Nuclear Medicine physicians about Radiopharmacy for their Board licensing exams. Pamela completed her Graduate Studies at the University Alberta, Edmonton with post-graduate research in Germany and is an Imaging Researcher at Lawson Health Research Institute. Executive and Board positions have been held within the Canadian Society of Nuclear Medicine, Society of Nuclear Medicine in Canada, Canadian Association of Radiopharmaceutical Sciences. Scientific Review of scientific publications, abstracts and grants have been performed for SNM, CANM and granting agencies. Along with 3 patents, Pam has 32 peer-reviewed journal articles, 47 invited lectures and 53 scientific presentations/abstracts. Pamela has 17 years of experience with final radiolabelling of sterile radionuclidic therapies for Neuroendocrine Cancer and provided invited lectures in the specialized field. She has been integrally involved with clinical therapy with Lu-177 DOTATATE for 4 years.